Imunotera

A startup develops the “Act-Tera” technology: a immune system based activation platform in the generation of T cells. This technology can be applied for the treatment of chronic infectious diseases, such as infections caused by HPV, HIV and SARS-CoV-2. An immunological platform generates products in the form of DNA, RNA or recombinant protein. One of these products is a TERAH-7, an immunotherapy that trains defense cells of the body to eliminate diseased cells, such as cancer
cervical cancer and head and neck cancer – both caused by HPV. This treatment, in addition to not being invasive, generates memory against cancer, preventing recurrences of the disease.

 

BUSINESS MODEL: Technology licensing for pharmaceuticals and partner companies and/or co-development.

 

PRODUCT: In development

 

STAGE: Validation

 

For further information, please contact us.

Back to Investors page